Health Condition 1: null- -Age 18 years and above -Written informed consent for participation - Hospitalized for acute coronary syndrome -Prior angioplasty or Prior bypass surgery
Conditions
Interventions
None listed
Sponsors
Merck Co Inc
Eligibility
Inclusion criteria
Inclusion criteria: DYSIS II ACS • Age >= 18 years • Hospitalized for acute coronary syndrome (ACS) (ST segment elevation myocardial infarction (STEMI), left bundle branch block (LBBB), Non-ST elevated myocardial infarction (NSTEMI), unstable angina) at time of enrolment • Full lipid profile available based on blood drawn within 24 hours of admission to the hospital. • On lipid-modifying therapy (LMT) for equal to or more than 3 months at time of enrolment, or NOT at all on LMT. DYSIS II CHD • Age >= 18 years • Documented CHD by at least one of the following: o coronary angiography (stenosis >50%) o cardiac computed tomography (CT) (stenosis > 50%) o prior percutaneous coronary intervention (PCI) or prior coronary artery bypass graft (CABG) o history of ACS >3 months prior to enrolment o Complete fasting lipid profile 0-12 months prior to enrollment while on lipid modifying therapy (LMT) for equal to or more than 3 months or not at all on LMT
Exclusion criteria
Exclusion criteria: DYSIS II ACS • Patients treated with lipid-modifying therapy for more than 0 but less than 3 months at the time of enrolment DYSIS II CHD • History of ACS within 3 months prior to enrollment • Participation in DYSIS II ACS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this observational study is to document real life lipid levels in patients with stable CHD (stable CHD or ACS) Timepoint: Time point for assessment for Stable CHD is when patient report or visit to treating physician for routine follow-up Time Point for Data collection of ACS patients - When patient is discharged after successful ACS treatment. Thereafter telephonic follow-up 16 weeks post discharge | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢To describe patient characteristics and risk profiles (associated comorbidities) in patients with stable CHD specifically chronic kidney disease (CKD stages 3-5) and type 2 diabetes mellitus (T2DM) and survivors of ACS â?¢To document drug utilization patterns for patients with CHD and among CHD subgroups (stable CHD, ACS, CKD, T2DM) â?¢To document goal achievements in CHD patients and among CHD subgroups (stable CHD, ACS, CKD, T2DM), treated and not treated with lipid-modifying therapy. Timepoint: â?¢ To describe patient characteristics and risk profiles (associated comorbidities) in patients with stable CHD specifically chronic kidney disease (CKD stages 3-5) and type 2 diabetes mellitus (T2DM) and survivors of ACS â?¢ To document drug utilization patterns for patients with CHD and among CHD subgroups (stable CHD, ACS, CKD, T2DM) â?¢ To document goal achievements in CHD patients and among CHD subgroups (stable CHD, ACS, CKD, T2DM), treated and not treated with lipid-modifying therapy. | — |
Countries
Belgium, Egypt, France, Germany, Greece, Hong Kong, India, Indonesia, Ireland, Italy, Jordan, Kuwait, Lebanon, Philippines, Republic of Korea, Russian Federation, Saudi Arabia, Singapore, Taiwan, Thailand, United Arab Emirates, Viet Nam
Contacts
Public ContactDr Samir Sadekar
Pacific Clinical Research India Pvt Ltd,
Outcome results
None listed